Ascletis Doses First Patient in ASC30 Phase III Obesity Trial

Ascletis has initiated dosing in its global Phase III trials for ASC30, a once-daily oral GLP-1 receptor agonist targeting obesity, aiming to become the second oral competitor to oral semaglutide in the U.S. and Europe with results expected by late 2028.

This Wire brief sits within Fusion42's coverage of Biotech.